Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Primary small intestinal lymphoma: Epidemiological, histological and therapeutic transition in Tunisia
Bulletin du Cancer, Volume 99, No. 4, Year 2012
Notification
URL copied to clipboard!
Description
Introduction. Primary small intestinal lymphoma (PSIL) is the second Non-Hodgkin lymphoma (NHL) of the digestive tract (after gastric NHL). Purpose. To evaluate during the past 28 years the epidemiological, anatomoclinical and therapeutic changes of PSIL in Tunisia through an acquired experience of more than a quarter of a century. Methods. Our retrospective study included patients with histologically confirmed small intestinal lymphoma from 1981 to 2008 in Tunisia at Salah Azaiz Institute. The cohort of 210 patients was divided into two groups: A group from 1981 to 1992 (152 patients) and B group from 1993 to 2008 (58 patients). We analysed the epidemiological, anatomoclinical, histological, and therapeutic characteristics. Results. We observed a significant decrease in the annual incidence of PSIL but also a significant transition of diffuse immunoproliferative small intestinal disease (IPSID) also known as "Mediterranean" PSIL, which were progressively replaced by "Western" lymphomas. Laparotomy with or without a debulking surgery, largely performed in group A, has disappeared at the cost of a primary chemotherapy (p<0.001). Five-year actuarial global and relapse free survivals were respectively 60.5 and 57.3%. Conclusion. PSIL in Tunisia were subjected to a triple transition: epidemiological, histological and therapeutic. ©John Libbey Eurotext.
Authors & Co-Authors
Belaid, Imtinene
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Mézlini, Amel
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Tunisia, Tunis
Association Tunisienne de Lutte Contre le Cancer Atcc
Raies, Henda
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Tunisia, Tunis
Association Tunisienne de Lutte Contre le Cancer Atcc
Jaafoura, Mohamed Habib
Tunisia, Manouba
Université de Tunis el Manar, Institut Mohamed Kassab D'orthopédie
Boussen, Hamouda
Tunisia, Ariana
Université de Tunis el Manar, Hôpital Abderrahmène Mami
Rifi, Hela
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Tunisia, Tunis
Association Tunisienne de Lutte Contre le Cancer Atcc
Ayadi, Mouna Sofiène
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Chraïet, Nesrine
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Daoud, Nouha
Tunisia, Tunis
Institut Salah Azaiez de Tunis
El Benna, Houda
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Ben-Ayed, Farhat
Tunisia, Tunis
Service D'oncologie Médicale
Tunisia, Tunis
Association Tunisienne de Lutte Contre le Cancer Atcc
Statistics
Citations: 11
Authors: 11
Affiliations: 5
Identifiers
Doi:
10.1684/bdc.2012.1549
ISSN:
00074551
e-ISSN:
17696917
Research Areas
Cancer
Health System And Policy
Study Design
Cohort Study
Study Locations
Tunisia